成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> ACS Applied Energy Materials >>article
ACS Applied Energy Materials

ACS Applied Energy Materials

IF: 5.4
Download PDF

Roxadustat: Not just for anemia.

Published:29 August 2022 DOI: 10.3389/fphar.2022.971795 PMID: 36105189
Xiaoyu Zhu, Lili Jiang, Xuejiao Wei, Mengtuan Long, Yujun Du

Abstract

Roxadustat is a recently approved hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated favorable safety and efficacy in the treatment of renal anemia. Recent studies found it also has potential for the treatment of other hypoxia-related diseases. Although clinical studies have not yet found significant adverse or off-target effects of roxadustat, clinicians must be vigilant about these possible effects. Hypoxia-inducible factor regulates the expression of many genes and physiological processes in response to a decreased level of oxygen, but its role in the pathogenesis of different diseases is complex and controversial. In addition to increasing the expression of hypoxia-inducible factor, roxadustat also has some effects that may be HIF-independent, indicating some potential off-target effects. This article reviews the pharmacological characteristics of roxadustat, its current status in the treatment of renal anemia, and its possible effects on other pathological mechanisms.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Roxadustat 808118-40-3 C19H16N2O5 361 suppliers $32.00-$6800.00

Similar articles

IF:3.2

Roxadustat for Patients with Post-transplant Anemia: A Narrative Review

Kidney Diseases Xiaoxiao Tang, Fei Liu,etc Published: 10 November 2023
IF:16.4

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.

Accounts of Chemical Research Tadao Akizawa, Yusuke Yamaguchi,etc Published: 1 October 2021
IF:16.4

Efficacy and Safety of Microsomal Ferric Pyrophosphate Supplement for Iron Deficiency Anemia in Pregnancy

Accounts of Chemical Research Ankita Srivastav, Shilpa Kshirsagar,etc Published: 28 March 2024